ProKidney Corp. (PROK) stock
PROKNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$1.04−0.06 (-5.45%)
Close on Nov 18, 2026Market cap $314.42MP/E –Yield –
ProKidney net income
Net income is the profit left for shareholders after every expense, interest and tax.
ProKidney's net income for the twelve months ending Jun 30, 2026 was -$84.16M. For fiscal 2025 it was -$68.99M.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$68.99M | – |
| FY2024 | Dec 31, 2024 | -$61.19M | – |
| FY2023 | Dec 31, 2023 | -$35.47M | – |
| FY2021 | Dec 31, 2021 | -$55.15M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$28.42M | – |
| Q1 FY2026 | Mar 31, 2026 | -$20.04M | – |
| Q4 FY2025 | Dec 31, 2025 | -$19.23M | – |
| Q3 FY2025 | Sep 30, 2025 | -$16.47M | – |
| Q2 FY2025 | Jun 30, 2025 | -$16.55M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.73M | – |
| Q4 FY2024 | Dec 31, 2024 | -$21.28M | – |
| Q3 FY2024 | Sep 30, 2024 | -$17.91M | – |
| Q2 FY2024 | Jun 30, 2024 | -$12.51M | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.49M | – |
| Q4 FY2023 | Dec 31, 2023 | -$5.70M | – |
| Q3 FY2023 | Sep 30, 2023 | -$10.98M | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.12M | – |
| Q1 FY2023 | Mar 31, 2023 | -$9.67M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.93M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$3.98M | – |
| Q3 FY2021 | Sep 30, 2021 | -$252.49K | – |
| Q2 FY2021 | Jun 30, 2021 | -$143 | – |
See a number that looks wrong?